1Pagel JF. Excessive daytime sleepiness[J]. Am Fam Physician, 2009,79(5) :391-396.
2Li S,Long J,Ma Z,et al. Assessment of the therapeutic activity of a combination of almitrine amd raubasine on functional rehabilitation following ischaemic stroke [J]. Curr Med Res Opin,2004,20(3) :409-415.
3Allain H, Bentue-Ferrer D. Clinical efficacy of almitrineraubasine[J]. European Neurology, 1998,39(Suppl 1) :39-44.
5Sachez AI, Buela-Casal G, Paz Bermudez M, et al. Effects of nCPAP treatment over reaction time and sleepiness levels during vigilance[J]. Clin Psychiatry, 2004,18(2) : 277-283.
6Stradling JR. Residual sleepiness in patients with OSA on CPAP [J].Eur Respir J,2009,34(5):1209.
7Yetkin O, Kunter E, Gunen H. CPAP compliance in patients with obstructive sleep apnea syndrome[J]. Sleep Breath,2008, 12(4):365-367.
8Krieger J, Mangin P, Kurtz D. Drug therapy for obstructive sleep apneas[J]. Am Rev Respir Dis,1984,129(4) :648-649.
1Wu S, Wang R, Ma X, et al. Excessive daytime sleepiness as- sessed by the Epworth Sleepiness Scale and its association with health related quality of life: a population-based study in China [ J ]. BMC Public Health,2012,12:849.
2Yue HJ, Mills PJ, Ancoli-Israel S, et al. The roles of TNF-alpha and the soluble TNF receptor I on sleep architecture in OSA [ J ]. Sleep Breath ,2009,13 ( 3 ) :263 - 269.
